TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03491579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy
Study: NCT03225547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
Study: NCT00836758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analysis with AED and manual PSG scoring
Description: The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
Study: NCT01093963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: oral; 20-70mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; 20-70mg/day
Study: NCT03792477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
Study: NCT03655535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTI320
Description: Non-systemic galactomannan complex polysaccharide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00495222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue plication
Description: Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Suturing System
Description: Tissue plication of dilated GJ stoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Plication
Description: Tissue plication for GJ stoma reduction
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 Lead ECG
Description: participant resting supine

Intervention type: OTHER
Group type: OTHER
Intervention: 12 Lead ECG
Description: participant resting supine
Study: NCT04685486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
Study: NCT00834405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA® 20 mg tablets
Description: 1 x 20 mg, single-dose non-fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets
Description: 1 x 20 mg, single-dose non-fasting
Study: NCT01643135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Study: NCT02161445

Intervention type: DEVICE
Intervention: the acoustic cardiographic parameters were calculated
Description: STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.

Intervention type: DEVICE
Intervention: the acoustic cardiographic parameters were calculated
Description: STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
Study: NCT01456221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega3 and an hypocaloric diet.
Description: Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil with an hypocaloric diet.
Description: Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
Study: NCT04817904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Description: The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
Study: NCT05612724

Intervention type: DEVICE
Group type: OTHER
Intervention: Testing for SARS CoV2 Antigen
Description: Device: Testing for SARS CoV2 Antigen Antigen testing: Rapid Antigen testing (Point-of-care)
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: Measured in the seated position after 5 minutes rest

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure and Heart Rate
Description: Measured in the seated position after 5 minutes rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arterial Stiffness
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study: NCT01656642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered q3w or q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort
Study: NCT03273972

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Stiffness
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study: NCT04533295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture and IVF
Description: Acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture and IVF
Description: Sham acupuncture was performed three times a week for 30 minutes each time, starting from the 5th day of menstruation and ending within 24 hours after embryo transfer.
Study: NCT01125137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Keloid
Description: Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
Study: NCT04046783

Intervention type: DEVICE
Intervention: patch
Description: an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.

Intervention type: DEVICE
Intervention: patch
Description: an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
Study: NCT01656642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central Haemodynamics
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study: NCT03967223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel (lete-cel, GSK3377794)
Description: letetresgene autoleucel will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel (lete-cel, GSK3377794)
Description: letetresgene autoleucel will be administered.
Study: NCT01656642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Oral repeating dose, depending on arm/cohort
Study: NCT03273972

Intervention type: OTHER
Group type: OTHER
Intervention: Central Haemodynamics
Description: Measure of functional and structural changes which accompanies cardiovascular disease
Study: NCT04091217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
Study: NCT03967223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as the lymphodepleting chemotherapy
Study: NCT02598414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-infrared ICG fluorescence imaging
Description: Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional bowel anastomosis
Description: Traditional bowel anastomosis will be performed without ICG fluorescence imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FireFly™
Description: The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
Study: NCT04495660

Intervention type: DEVICE
Group type: OTHER
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort

Intervention type: DEVICE
Group type: OTHER
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
Study: NCT03967223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as the lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as the lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Study: NCT04495660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near InfraRed Spectroscopy (fNIRS)
Description: Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Passive perceptual stimulation
Description: Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
Study: NCT01114893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004%
Description: 1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost Vehicle
Description: 1 drop in each eye 8 times daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost (Groups A, B and C)
Description: 1 drop in each eye 8 times daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost (Groups A, B and C)
Description: 1 drop in each eye 8 times daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost (Groups A, B and C)
Description: 1 drop in each eye 8 times daily for 5 days
Study: NCT03405454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy
Description: chemotherapy treatment will be administered as per local institutional guidelines
Study: NCT01759277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Femoral perineural local anesthetic infusion
Description: The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
Study: NCT01759277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Adductor Canal perineural local anesthetic infusion
Description: The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
Study: NCT00355797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Stimulation (CLS)
Description: Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid Intima Media Thickness
Description: Measurements will be repeated three times, and the average of the median values will be recorded

Intervention type: OTHER
Group type: OTHER
Intervention: Carotid Intima Media Thickness
Description: Measurements will be repeated three times, and the average of the median values will be recorded

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm blood flow studies
Description: Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability

Intervention type: OTHER
Group type: OTHER
Intervention: Forearm blood flow studies
Description: Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant medication check
Description: Review of medication taken by the participant

Intervention type: OTHER
Group type: OTHER
Intervention: Concomitant medication check
Description: Review of medication taken by the participant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication compliance check (Pill count)
Description: Ensure prescribed statin has been taken

Intervention type: OTHER
Group type: OTHER
Intervention: Medication compliance check (Pill count)
Description: Ensure prescribed statin has been taken

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: Check overall health

Intervention type: OTHER
Group type: OTHER
Intervention: Physical examination
Description: Check overall health

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical history
Description: Review of volunteers medial history

Intervention type: OTHER
Group type: OTHER
Intervention: Medical history
Description: Review of volunteers medial history

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AE/SAE review & reporting
Description: Monitor safety from the point of consent
Study: NCT01101191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 80-mg tablet x 1 dose taken without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
Study: NCT03520127

Intervention type: DEVICE
Intervention: Intact Breast Lesion Excision System (BLES)
Description: Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
Study: NCT03556488

Intervention type: DIAGNOSTIC_TEST
Intervention: US air bronchogram score
Description: On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment.